BIOXYTRAN Business Summary

Bioxytran, Inc. (BIXT) is a clinical-stage biopharmaceutical company that generates revenue through a hybrid model of strategic licensing, research collaborations, and a recently launched commercial nutraceutical division. The company operates across three primary business segments: Glycovirology, focused on galectin-inhibiting antivirals like ProLectin-M; Hypoxia, developing oxygen-transport therapies such as BXT-25 for stroke and wound healing; and Nutraceuticals, which transitioned to a commercial phase in February 2026 via a distribution agreement with Khoury Medical LTD for its blood-sugar management supplement, A-SUQAR. Bioxytran competes directly with firms such as Tonix Pharmaceuticals, CellPhire, and Cyclerion Therapeutics, positioning itself as a specialized leader in carbohydrate-based drug design and galectin-targeting platform technologies. The leadership team is anchored by Founder and CEO David Platt, Ph.D., a world-renowned expert in carbohydrate chemistry who previously founded three publicly traded companies, including Galectin Therapeutics (GALT), and has a track record of raising over $150 million in public markets. He is supported by CFO Ola Soderquist, a senior finance professional with over 30 years of experience at major international firms including Ericsson and Electrolux, and Chief Medical Officer Dr. Leslie Ajayi, who brings two decades of clinical development expertise. The company’s strategic direction is further guided by a board that includes independent director Alan Hoberman and scientific advisors like tissue physiology authority Prof. Avraham Mayevsky, while maintaining high-profile research collaborations with the University of Georgia and the University of Minnesota.